To help you understand what is going on with the FDA approval of Zepbound, Eli Lily’s new weight-loss drug and in the pharmaceutical sector as a whole, our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest…
There’s starting to be a bit of price relief for high-cost weight-loss drugs. Eli Lilly’s newly approved weight-loss drug will be a little cheaper than Novo Nordisk’s Wegovy, which costs just over $1,790 per injection. Lilly’s drug, which will be marketed as Zepbound, recently got federal approval for weight loss, and its list price is about 20% less than Wegovy. Look for future rounds of discounting.
